The discovery of the endocannabinoid system, comprising the G‐protein coupled
cannabinoid 1 and 2 receptors (CB 1/2), their endogenous lipid ligands or …

Prospective epidemiological studies have consistently demonstrated that cannabis use is
associated with an increased subsequent risk of both psychotic symptoms and …

Psychiatric disorders like mood disorders, schizophrenia, or drug addiction affect a sizeable
proportion of the human population and severely compromise quality of life. Therefore …

Endocannabinoids play an important role in a diverse range of neurophysiological
processes including neural development, neuroimmune function, synaptic plasticity, pain …

Over recent years, the interest in the endocannabinoid system (ECS) as a new target for the
treatment of schizophrenia has evolved. The ECS represents one of the most relevant …

With recent studies using genetic, epigenetic, and other molecular and neurochemical
approaches, a new era has begun in understanding pathophysiology of suicide. Emerging …

Impaired cognitive functioning, including deficits in working memory, is considered to be a
core and disabling feature of schizophrenia that is difficult to treat. Deficits in working …

Understanding the human brain is the ultimate goal in neuroscience, but this is extremely
challenging in part due to the fact that brain tissue obtained from autopsy is practically the …

Objective: Certain cognitive deficits in individuals with schizophrenia have been linked to
disturbed gamma-aminobutyric acid (GABA) and glutamate neurotrans-mission in the …

Cannabis use has been reported to increase the risk of developing schizophrenia and to
worsen symptoms of the illness. Both of these outcomes might be attributable to the …